Across TCGA pan-cancer cohorts, ASPRV1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ASPRV1 data layer compared with 24 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ASPRV1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ASPRV1 expression acts as an unfavorable survival marker.
HNSC are the cancer types where ASPRV1 mass-spec protein most reproducibly stratifies survival.